Results of Late-Stage Trial Lead to End of GSK’s HSV Vaccine

GlaxoSmithKline (GSK) is halting development of Simplirix, a vaccine to prevent herpes in women that showed promise in early trials, but which failed in a pivotal trial. Despite earlier trial data indicating the vaccine was 70 percent effective, Phase III results showed the vaccine was 20 percent effective, according to NIH’s National Institute of Allergy and Infectious Diseases, which co-sponsored the study with GSK. The study failed to meet statistical significance for the primary endpoint, prevention of genital herpes disease, GSK says.
Clinical Trials Advisory